NeuroSense Therapeutics Past Earnings Performance
Past criteria checks 0/6
NeuroSense Therapeutics's earnings have been declining at an average annual rate of -34.8%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-34.8%
Earnings growth rate
-10.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Nov 17NeuroSense Therapeutics GAAP EPS of -$0.55
Aug 31We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
Jul 06NeuroSense climbs 66% after early data supporting Alzheimer’s candidate
Jun 30Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Mar 31NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans
Mar 22NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Dec 22Revenue & Expenses Breakdown
How NeuroSense Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -10 | 5 | 7 |
| 31 Mar 24 | 0 | -13 | 5 | 7 |
| 31 Dec 23 | 0 | -10 | 5 | 7 |
| 30 Sep 23 | 0 | -11 | 6 | 7 |
| 30 Jun 23 | 0 | -11 | 4 | 6 |
| 31 Mar 23 | 0 | -14 | 7 | 7 |
| 31 Dec 22 | 0 | -10 | 5 | 6 |
| 30 Sep 22 | 0 | -9 | 7 | 5 |
| 30 Jun 22 | 0 | -7 | 6 | 4 |
| 31 Mar 22 | 0 | -5 | 4 | 2 |
| 31 Dec 21 | 0 | -3 | 2 | 1 |
| 30 Sep 21 | 0 | -5 | 1 | 4 |
| 30 Jun 21 | 0 | -5 | 1 | 4 |
| 31 Mar 21 | 0 | -5 | 0 | 4 |
| 31 Dec 20 | 0 | -3 | 0 | 2 |
Quality Earnings: NRSN is currently unprofitable.
Growing Profit Margin: NRSN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NRSN is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.
Accelerating Growth: Unable to compare NRSN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NRSN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NRSN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.